- THE PROBLEM
- CHALLENGES OF TREATMENT
- FUTURE GOALS IN DIABETES
Intarcia Platform Technology
The DUROS device is a subcutaneous osmotic mini-pump. Each device contains an appropriate volume of drug product to treat a patient for a predetermined extended duration of time.
Key Executive Appointments
April 02, 2012
Expanded Appointment For Kurt Graves as Chairman, President and Chief Executive Officer
March 27, 2012
Michelle Baron, MD, FACE Joins Intarcia as VP and Chief Medical Officer
Message from the CEO
Intarcia is quickly developing into a fully integrated biopharmaceutical company with a high-growth future. We are making decisive strides toward better disease management, as evidenced by our progress with ITCA 650, our late-stage development product for type 2 diabetes. We focus on differentiated products with our breakthrough technology platform and key partner relationships. Share our excitement by staying tuned to all our milestones of progress as we realize our aspirations for the future.
